Compare APGE & OBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APGE | OBDC |
|---|---|---|
| Founded | 2022 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.6B |
| IPO Year | 2023 | 2015 |
| Metric | APGE | OBDC |
|---|---|---|
| Price | $134.08 | $10.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 8 |
| Target Price | ★ $109.67 | $14.00 |
| AVG Volume (30 Days) | ★ 5.4M | 3.8M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 13.40% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.34 | $10.52 |
| 52 Week High | $134.35 | $14.85 |
| Indicator | APGE | OBDC |
|---|---|---|
| Relative Strength Index (RSI) | 80.75 | 44.60 |
| Support Level | $80.52 | $10.62 |
| Resistance Level | N/A | $11.27 |
| Average True Range (ATR) | 0.43 | 0.22 |
| MACD | -1.69 | 0.01 |
| Stochastic Oscillator | 86.53 | 18.55 |
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Blue Owl Capital Corp is a specialty finance company and business development company (BDC) focused on providing direct lending solutions to U.S. middle-market companies. The company seeks to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns, including senior secured, subordinated, or mezzanine loans and equity-related instruments. Its investment strategies are intended to generate favorable returns across credit cycles with an emphasis on preserving capital.